Value Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jurgis Bekepuris who wrote (56629)	1/12/2016 1:03:38 AM
From: E_K_S	of 78708

Achaogen, Inc. (AKAO) Tekla Healthcare Opportunities Fund (THQ) - small add to this Pharma CEF Fund. I started a small position in this Bio-Tech stock (AKAO). The stock got to my But price of $5.18/share. The only value proposition is that they have $3.84/share in cash and two Phase III candidate drugs in the pipeline. I have been following the company for over a year since the FDA wanted them to broaden the scope of their original Phase III trial. That has/will require a lot of cash but they still probably have enough money to complete that before they may need to raise more money. It's a small position. My oil and natural resource stocks continue to sell off, so I am focused on other sectors. Also added a few more shares to THQ as it sold off w/ the rest of the market. Their top 10 holdings look ok and seem to be over sold. EKS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next